Q-omics provides the consensus-scored PRR22 profile across patient tissues and cancer cell-line models. PRR22 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PRR22 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, PRR22 RNA expression shows 16,500 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, COAD, and THYM as cancer lineages where PRR22 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRR22 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRR22 survival associations across molecular data types. PRR22 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRR22 RNA expression–survival associations across cancer types. High PRR22 expression shows unfavorable associations in ACC, PRAD and LUAD, but favorable associations in UVM, PAAD and CESC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PRR22 RNA expression.
This table summarizes PRR22 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for PRR22. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRR22 shows higher tumor expression in COAD, KIRC, STAD, UCEC, KIRP and LUSC. The COAD box plot shows higher PRR22 RNA expression in tumor versus normal tissue (log2 FC = +1.174, t-test p < 0.001).
This table shows molecular features associated with PRR22 in patient tissues and cancer cell lines. In patient samples, PRR22 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, PRR22 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BONE and SOFT_TISSUE.
